RELB and Miyoshi myopathy: While G9a-based therapy will likely require combination based therapy with other MM drugs, targeting G9a to selectively inhibit RelB or NF-κB pathway only in MM cells may come with less toxic adverse effects than current broader therapeutic approaches.